CIU

Novartis’s omalizumab met all primary and secondary endpoints in pivotal GLACIAL study of patients with severe form of chronic skin disease CSU

Omalizumab met all primary and secondary endpoints in pivotal GLACIAL study of patients with refractory chronic spontaneous urticaria (CSU)[1] Omalizumab…

11 years ago